When do the patents on AMINOSYN 7% (PH6) expire, and when will generic AMINOSYN 7% (PH6) be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Icu Medical Inc	AMINOSYN 7% (PH6)	amino acids	INJECTABLE;INJECTION	017673-006	Nov 18, 1985		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 16, 2026

AMINOSYN 7% (PH6) is an amino acid injection product used in parenteral nutrition, typically positioned in the sterile IV generics and complex-drug supply chain. Investment due diligence is driven by (1) FDA regulatory status and Orange Book listings (for exclusivity and listed patents), (2) sterile manufacturing and supply reliability, (3) whether listed patents and exclusivities block generic entry, and (4) competitive pricing and pass-through reimbursement pressure for TPN amino acid components.

What is AMINOSYN 7% (PH6) and how does it generate revenue?

Featured snippet answer: AMINOSYN 7% (PH6) is an amino acid injection formulation for parenteral nutrition (PN/TPN), sold into hospitals, home infusion, and institutional purchasing channels where contract pricing and formulary access set most economics.

What is the drug’s therapeutic role in parenteral nutrition?

Amino acids are core nitrogen sources in PN solutions.
Product economics in this category often track:
- inpatient PN utilization,
- acuity mix (ICU, oncology, surgery, neonates),
- length of stay and discharge patterns,
- competing PN components (dextrose, electrolytes, lipids, multi-chamber PN).

Where does demand come from?

Hospitals and IDNs buy through GPO and contract pharmacy networks.
Home infusion markets matter where patients are on long-term PN.
Demand is capacity-driven: sterile filling, cold-chain is usually not the main constraint for amino acids compared with some biologics, but aseptic processing and batch release are.

What fundamentals matter for valuation in sterile injectables?

Gross-to-net compression from contracting and rebates.
Manufacturing yield and deviation history (sterile plants).
Lead times for key raw materials and container closure systems.
FDA inspection posture and compliance record.
Ability to maintain uninterrupted supply during line downtime.

What is the Orange Book status of AMINOSYN 7% (PH6)?

Featured snippet answer: No complete, citable Orange Book patent/exclusivity dataset is provided in the available information, so the Orange Book listing status, listed patents, and exclusivity expiration dates for AMINOSYN 7% (PH6) cannot be mapped here.

How investors should interpret Orange Book listings for this category

When Orange Book data is available, the key fields are:

Drug product reference name match
Dosage form and strength mapping (7% amino acid injection; any PH6 pH designation)
Patent list type:
- composition of matter,
- formulation,
- method of use,
- manufacturing process,
- packaging
Patent expiration and exclusivity end dates
Whether ANDA applicants have Paragraph IV certifications

What signals matter most for future generic entry

Presence of method-of-use patents is unusual for amino acid injections but can occur via nutritional regimens.
Formulation and manufacturing patents can materially delay generic approval even when active ingredient is off-patent.
If exclusivity (3-year, 5-year) is asserted for a change, it can block shorter-cycle competitors.

What patents protect AMINOSYN 7% (PH6), and when do they expire?

Featured snippet answer: Patent numbers, assignees, and expiration dates for AMINOSYN 7% (PH6) are not provided in the available information, so a defensible patent-expiration map cannot be produced.

Patent estate structure investors typically audit for PN amino acid products

Composition claims (rarely durable because amino acid building blocks are old).
Formulation claims (pH, osmolality targets, stabilizers, ion balance, buffering systems).
Manufacturing/process claims (sterilization method, filtration, hold times, aseptic processing parameters).
Container/closure system claims (less common but can be present for sterile products).

What to model in an investment case once patents are known

Blocking versus non-blocking patents for generic entrants.
Likely design-around space:
- buffer system changes,
- pH and tonicity adjustments,
- manufacturing process parameter shifts.
Litigation risk:
- likelihood of sustained injunctions versus “win-and-lose” schedules.

When does AMINOSYN 7% (PH6) lose exclusivity and patent protection?

Featured snippet answer: Exclusivity and patent-loss dates cannot be established from the information provided, so any exclusivity timeline would be non-actionable.

Timing variables to include in scenario analysis

Earliest “patent first expiration” versus “last-to-expire” for the reference listed drug.
180-day exclusivity grant status (if a Paragraph IV filer is eligible).
Potential pediatric exclusivity extensions.
Any settlement “carve-out” schedules if litigation resolves via agreement.

How strong is the patent estate for AMINOSYN 7% (PH6)?

Featured snippet answer: Without the patent portfolio (listed patents and any litigated patents), patent-strength scoring cannot be produced.

Investors’ typical patent strength scoring inputs

Number of active, unexpired Orange Book-listed patents.
Claim scope breadth:
- broad genus formulation versus narrow pH/osmolality window.
Manufacturing/process enforceability:
- whether process steps are observable in product records and batch release.
Prior art density:
- obviousness risk for composition and formulation patents.
Litigation history:
- outcomes and whether courts construed claims narrowly.

What generic entry risks exist for AMINOSYN 7% (PH6)?

Featured snippet answer: Generic entry risk cannot be quantified without Orange Book and ANDA/Paragraph IV data.

Key risk framework to apply once entry data is available

Does the reference product have at least one unexpired, enforceable formulation or manufacturing patent?
Has any ANDA filed Paragraph IV?
Are there current 505(b)(2) or 505(j) competitors with “no carve-out” designs?
Is the market already crowded with therapeutically equivalent amino acid injections?
- If yes, risk is pricing pressure rather than total launch blocking.

What changes the risk in sterile products

FDA chemistry, manufacturing, and controls (CMC) burden:
- sterile fill-finish qualification can be the limiting factor.
Batch release timelines and market allocation:
- new entrants may face constrained volume, leading to “limited competition” early.

What FDA regulatory status and approval pathway does AMINOSYN 7% (PH6) have?

Featured snippet answer: FDA approval pathway, reference product mapping, and any post-approval supplements are not specified in the available information, so pathway-based scenarios cannot be built.

What investors should verify in FDA records

Whether AMINOSYN 7% (PH6) is the reference listed drug (RLD).
Current label and any recent changes:
- formulation adjustments,
- sterility/process changes,
- packaging changes.
Any recalls or warning letters affecting supply continuity.

How does AMINOSYN 7% (PH6) compare with other amino acid injection products?

Featured snippet answer: A comparative product-and-estate analysis cannot be completed without competitor reference products, strengths, and FDA/Orange Book mappings.

Comparison dimensions investors use

Unit pricing and contract pricing across hospitals.
Substitution likelihood in PN compounding:
- pharmacy substitution rules,
- automated PN compounding compatibility,
- perceived differences in tolerability (if label supports it).
Supply reliability and backorder frequency.

What manufacturing/IP barriers affect supply and margins for AMINOSYN 7% (PH6)?

Featured snippet answer: Manufacturing location, facility inspection posture, and CMC filing details are not provided, so barrier assessment cannot be made.

Typical sterile-injectable barriers investors should model

Aseptic processing capability and yields.
Sterility assurance testing throughput and failure rates.
Component sourcing (bags/vials, stoppers, tubing).
Stability profile and shelf-life (affects inventory carrying and ordering cycles).

Which companies compete with AMINOSYN 7% (PH6), and how intense is pricing pressure?

Featured snippet answer: Competitor set and current market shares are not provided, so competitive intensity cannot be ranked.

What drives competitive intensity in PN amino acids

Multiple generic players can commoditize pricing once regulatory barriers fall.
Hospitals shift among suppliers based on:
- GPO contracts,
- formulary preference,
- delivery performance and lot-to-lot consistency.
If one supply chain falters, temporary market share swings can occur.

What patent litigation affects AMINOSYN 7% (PH6), and what settlements matter?

Featured snippet answer: Litigation docket status, parties, and settlement terms are not provided.

What to extract when litigation records exist

Case number, court, and claim-construction outcomes.
“Dismissed without prejudice” versus adjudicated invalidity or non-infringement.
Settlement “design-around” schedules (launch dates, carve-outs, volume limitations).
Whether patents were litigated as part of a broader PN family.

Investment scenario: upside and downside cases for AMINOSYN 7% (PH6)

Featured snippet answer: A two-scenario financial model cannot be built from the provided information because the core drivers needed for valuation (Orange Book patent/exclusivity timeline, ANDA landscape, litigation, and competitor set) are not specified.

Downside scenario mechanics investors usually underwrite

Entry of one or more ANDA competitors after patent/exclusivity loss.
Rapid conversion to lowest-contract pricing.
Gross-to-net erosion from rebates and customer incentives.
Supply shocks that increase costs of goods or force allocation.

Upside scenario mechanics investors underwrite

Extended exclusivity or enforceable formulation/process patents delay generic entry.
Limited capacity or quality events constrain competitors, allowing pricing power.
Facility upgrades extend shelf life and reduce cost per batch.
Contract wins in large IDNs sustain volume and reduce lead risk.

What due-diligence checklist should investors run before underwriting AMINOSYN 7% (PH6)?

Featured snippet answer: The checklist is driven by three evidence sets that are not provided here: Orange Book/ANDA dataset, litigation/settlement records, and supply-chain/compliance documentation.

Evidence set 1: Exclusivity and patent barriers

Identify the RLD name for AMINOSYN 7% (PH6).
Extract all Orange Book listed patents with expiration dates.
Capture Paragraph IV filings, certifications, and FDA status.
Record any pediatric or other exclusivity extensions.

Evidence set 2: Legal enforceability

Confirm which patents are litigated and current case posture.
Extract claim construction outcomes.
Validate whether any settlement triggers earlier generic entry for some products.

Evidence set 3: Product supply and COGS durability

Facility inspection outcomes and remediation history.
Batch yield trends and deviation frequency.
Backorder and allocation history by lot.

Key Takeaways

AMINOSYN 7% (PH6) is a sterile amino acid injection product whose investment case depends primarily on FDA exclusivity/patent barriers, generic-competition timing, and supply chain quality.
The information provided does not include the Orange Book, patent list, exclusivity dates, ANDA Paragraph IV landscape, litigation, or competitor set required to produce an actionable patent-expiration and generic-entry scenario.
Without those evidence sets, valuation cannot be grounded in defensible “time to generic erosion” and enforceability assumptions.

FAQs

How do Orange Book listed patents usually affect ANDA approvals for sterile amino acid injections?
What manufacturing and aseptic processing CMC issues most often delay generic entry for IV sterile products?
How does 180-day exclusivity from Paragraph IV filings change pricing risk in hospital injectables?
What types of formulation changes can design around pH/osmolality or buffer-related patents for nutritional injectables?
How do settlement agreements in ANDA litigation typically structure launch timing and carve-outs for competing sterile products?

References (APA)

FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. (n.d.). Paragraph IV: Overview of ANDA patent certifications. U.S. Food and Drug Administration. https://www.fda.gov/
FDA. (n.d.). Abbreviated New Drug Applications (ANDAs). U.S. Food and Drug Administration. https://www.fda.gov/

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for AMINOSYN 7% (PH6)